Evidence map›Paper›PMID 32393252›Full record

Trial reportLipids in health and disease2020

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).

Xiang Zhang, Lotte C A Stiekema, Erik S G Stroes, Albert K Groen

Registry-linked trialOpen access · goldFull text readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lipids in health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02729025. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02729025 phase3completed

A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)

Ran2016Enrolled129Registered outcomes4Posted comparisons4ConditionsSubjects With Hyperlipidemia, DyslipidemiaArmsEvolocumab, Placebo
PMID 30561610other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Xiang ZhangDepartment of Experimental Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. xiang.zhang@wur.nl.
Lotte C A StiekemaDepartment of Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Erik S G StroesDepartment of Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Albert K GroenDepartment of Experimental Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
University Medical Center · USUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as lipoprotein subclasses, amino acids and fatty acids remain to be characterized.

methodsWe performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30 individuals with elevated Lp(a) (> 150 mg/dL). The 30 participants were randomly assigned into two groups, placebo (N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420 mg Q4W treatment on circulating metabolites by running lognormal regression analyses, and compared this to placebo. Subsequently, we assessed the interrelationship between Lp(a) and 14 lipoprotein subclasses in response to treatment with evolocumab, by running multilevel multivariate regression analyses.

resultsOn average, evolocumab treatment for 16 weeks resulted in a 17% (95% credible interval: 8 to 26%, P < 0.001) reduction of circulating Lp(a), coupled with substantial reduction of VLDL, IDL and LDL particles as well as their lipid contents. Interestingly, increasing concentrations of baseline Lp(a) were associated with larger reduction in triglyceride-rich VLDL particles after evolocumab treatment.

conclusionsInhibition of PCSK9 with evolocumab markedly reduced VLDL particle concentrations in addition to lowering LDL-C. The extent of reduction in VLDL particles depended on the baseline level of Lp(a). Our findings suggest a marked effect of evolocumab on VLDL metabolism in subjects with elevated Lp(a).

trial registrationClinical trial registration information is registered at ClinicalTrials.gov on April 14, 2016 with the registration number NCT02729025.

Indexed as

PCSK9 InhibitorsAgedAntibodies, Monoclonal, HumanizedCholesterol, HDLCholesterol, LDLCholesterol, VLDLFemaleGene ExpressionHumansHyperlipidemiasHypolipidemic AgentsLipid MetabolismLipoprotein(a)Magnetic Resonance SpectroscopyMaleMetabolomeAntibodies, Monoclonal, HumanizedCholesterol, HDLCholesterol, LDLCholesterol, VLDLevolocumabHypolipidemic AgentsLipoprotein(a)PCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9TriglyceridesEvolocumabLipoprotein(a)MetabolomicsPCSK9 antibodiesVLDL

Identifiers

PMID32393252
PMCPMC7216641
OpenAlexW3026029514

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.